Denna sida på svenska
Loading profile information...

About me

I am currently Assistant professor in Pr. Agneta’s Nordberg group. My main area of research is the in vitro characterization of novel PET tracers using autoradiography and binding assay. I defended my PhD in neuroscience in University Claude Bernard Lyon 1, France, in Pr Luc Zimmer group. The focus of my PhD was characterization of new PET tracers for serotoninergic receptor 5HT1a and 5HT7 using autoradiography and in vivo PET on rat and cat. During a first postdoc in University of Pennsylvania, Philadelphia, I worked on characterization of new SPECT ligands for serotoninergic transporter in Pr. Hank Kung laboratory. In 2013, I started a second post doc, here, in Agneta Nordberg’s group, with more focus on Alzheimer disease and more precisely, the characterization of new PET tracers for Tau deposits. 


Research description

Our main interest is to understand more clearly the different binding properties of the different tau PET tracers in human postmortem brain tissue from sporadic and familial AD cases as well as non-AD tauopathies, using autoradiography and binding assay techniques. We also have an interest to compare the tau deposits with other hallmarks of AD such as amyloid plaques and activated astrocytes.


Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
Murugan Na, Chiotis K, Rodriguez-vieitez E, Lemoine L, Ågren H, Nordberg A
European journal of nuclear medicine and molecular imaging 2019;():-

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease
Leuzy A, Cicognola C, Chiotis K, Saint-aubert L, Lemoine L, Andreasen N, et al
European journal of nuclear medicine and molecular imaging 2019;46(5):1152-1163

Tau PET imaging in neurodegenerative tauopathies-still a challenge
Leuzy A, Chiotis K, Lemoine L, Gillberg Pg, Almkvist O, Rodriguez-vieitez E, et al
Molecular psychiatry 2019;():-

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
Lemoine L, Leuzy A, Chiotis K, Rodriguez-vieitez E, Nordberg A
Alzheimer's & dementia (Amsterdam, Netherlands) 2018;10():232-236

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
Lemoine L, Gillberg Pg, Svedberg M, Stepanov V, Jia Z, Huang J, et al
Alzheimer's research & therapy 2017;9(1):96-

Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography
Lemoine L, Saint-aubert L, Nennesmo I, Gillberg Pg, Nordberg A
Scientific reports 2017;7():45496-

Development of [11C]/[3H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand
Stepanov V, Svedberg M, Jia Z, Krasikova R, Lemoine L, Okamura N, et al
Nuclear medicine and biology 2017;46():50-53

Tau PET imaging: present and future directions
Saint-aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-vieitez E, Nordberg A
Molecular neurodegeneration 2017;12(1):19-

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue
Lemoine L, Saint-aubert L, Marutle A, Antoni G, Eriksson Jp, Ghetti B, et al
Acta neuropathologica communications 2015;3():40-

A new single-photon emission computed tomography (SPECT) imaging agent for serotonin transporters: [(125)I]Flip-IDAM, (2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol
Zheng P, Lieberman Bp, Ploessl K, Lemoine L, Miller S, Kung Hf
Bioorganic & medicinal chemistry letters 2013;23(3):869-72

Characterization of FlipIDAM as a SERT-selective SPECT imaging agent
Lemoine L, Lieberman Bp, Ploessl K, Zheng Pg, Kung Hf

MPTP animal model of Parkinsonism: dopamine cell death or only tyrosine hydroxylase impairment? A study using PET imaging, autoradiography, and immunohistochemistry in the cat
Aznavour N, Cendres-bozzi C, Lemoine L, Buda C, Sastre Jp, Mincheva Z, et al
CNS neuroscience & therapeutics 2012;18(11):934-41

Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging
Lemoine L, Becker G, Vacher B, Billard T, Lancelot S, Newman-tancredi A, et al
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(6):969-76

Comparison of 4 radiolabeled antagonists for serotonin 5-HT(7) receptor neuroimaging: toward the first PET radiotracer
Lemoine L, Andries J, Le Bars D, Billard T, Zimmer L
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(11):1811-8

Synthesis and biological evaluation of potential 5-HT(7) receptor PET radiotracers
Andries J, Lemoine L, Le Bars D, Zimmer L, Billard T
European journal of medicinal chemistry 2011;46(8):3455-61

[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging
Lemoine L, Verdurand M, Vacher B, Blanc E, Le Bars D, Newman-tancredi A, et al
European journal of nuclear medicine and molecular imaging 2010;37(3):594-605

Looking for a 5-HT7 radiotracer for positron emission tomography
Andries J, Lemoine L, Mouchel-blaisot A, Tang S, Verdurand M, Le Bars D, et al

Functional correlates for 5-HT(1A) receptors in maternally deprived rats displaying anxiety and depression-like behaviors
Lambás-señas L, Mnie-filali O, Certin V, Faure C, Lemoine L, Zimmer L, et al
Progress in neuro-psychopharmacology & biological psychiatry 2009;33(2):262-8

Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand
Tang S, Verdurand M, Joseph B, Lemoine L, Daoust A, Billard T, et al
Nuclear medicine and biology 2007;34(8):995-1002

Show all publications